Meanwhile, genetic testing using intracranial cancer tissues recognized a mutation of EGFR 19DEL, programmed cell death ligand-1  < 1% by SP263 antibody, microsatellite stable, a level of 3.6 Mut/Mb in tumor mutation burden and murine double minute 2 amplification (7.33 times). This evidence concerns the gene EGFR and neoplasm.